Search results
Results From The WOW.Com Content Network
Sir Cosmo Duff Gordon's testimony was a highlight of the inquiry, attracting many society figures. During 36 days of official investigations (spread over two months), testimony was recorded from nearly 100 witnesses in the form of answers to set questions that the process was designed to answer.
Sir Cosmo Edmund Duff-Gordon, 5th Baronet, DL (22 July 1862 – 20 April 1931) was a prominent Englishman and sportsman who owned land in Scotland, best known for the controversy surrounding his escape from the sinking of the RMS Titanic .
Alma mater. St Peter's College, Oxford. University of London. Sir Gordon William Duff, FRCP, FMedSci, FRSE (born 27 December 1947) is a British medical scientist and academic. He was principal of St Hilda's College, Oxford, from 2014 to 2021. He was Lord Florey Professor of Molecular Medicine at the University of Sheffield from 1991 to 2014.
The report stated: The very gross charge against Sir Cosmo Duff Gordon that, having got into No. 1 boat, he bribed the men in it to row away from the drowning people, is unfounded. The report, however, admonished the occupants of Boat 1 for not making an effort to rescue survivors from the water.
Lucy Christiana, Lady Duff-Gordon (née Sutherland; 13 June 1863 – 20 April 1935) was a leading British fashion designer in the late 19th and early 20th centuries who worked under the professional name Lucile . The first British-based designer to achieve international acclaim, Lucy Duff-Gordon was a widely acknowledged innovator in couture ...
A letter written by Titanic survivor Lucy Lady Duff-Gordon is slated to hit the auction block in Boston.
Thomas Packenham records that the Gordon's lost 100 men in 10 minutes. Regimental history records that “Captain Meyrick and 19 men were killed, with 78 men wounded”. Gordon-Duff recorded that “… our dead and wounded numbered 97. Later, 15 or 16 died of wounds and another four or five died of wounds in hospital.”
Theralizumab (also known as TGN1412, CD28-SuperMAB, and TAB08) is an immunomodulatory drug developed by Thomas Hünig of the University of Würzburg. It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by Parexel in London in March 2006. [1]